Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art.
Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci AD, Cimadamore A, Scarpelli M, Bonucci C, Andrini E, Errani C, Santoni M, Montironi R, Massari F. Mollica V, et al. Among authors: rosellini m. Cancers (Basel). 2021 Feb 1;13(3):546. doi: 10.3390/cancers13030546. Cancers (Basel). 2021. PMID: 33535541 Free PMC article. Review.
Treating Prostate Cancer by Antibody-Drug Conjugates.
Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Rosellini M, et al. Int J Mol Sci. 2021 Feb 4;22(4):1551. doi: 10.3390/ijms22041551. Int J Mol Sci. 2021. PMID: 33557050 Free PMC article. Review.
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A, Mollica V, Santoni M, Ricci AD, Rosellini M, Marchetti A, Montironi R, Ardizzoni A, Massari F. Rizzo A, et al. Among authors: rosellini m. Eur Urol Focus. 2022 Mar;8(2):514-521. doi: 10.1016/j.euf.2021.03.001. Epub 2021 Mar 11. Eur Urol Focus. 2022. PMID: 33714725 Review.
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.
Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, Fiorentino M, Battelli N, Santoni M, Massari F. Rizzo A, et al. Among authors: rosellini m. Pathol Res Pract. 2021 Jun;222:153440. doi: 10.1016/j.prp.2021.153440. Epub 2021 Apr 9. Pathol Res Pract. 2021. PMID: 33857854
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Rizzo A, et al. Among authors: rosellini m. Immunotherapy. 2021 Jun;13(9):783-793. doi: 10.2217/imt-2021-0005. Epub 2021 Apr 28. Immunotherapy. 2021. PMID: 33906376
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Santoni M, Rizzo A, Mollica V, Rosellini M, Marchetti A, Fragomeno B, Battelli N, Massari F. Santoni M, et al. Among authors: rosellini m. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):45-51. doi: 10.1080/14737167.2021.1937130. Epub 2021 Jun 15. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 34058953 Clinical Trial.
46 results